Alcon Inc.
0A0D.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$31.27B
Close$
$34.07
35.7% downside
Current Fair Value
35.7% downsideOvervalued by 35.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $31.27 Billion |
|---|---|
| Enterprise Value | $35.21 Billion |
| Dividend Yield | $0.28 (0.56%) |
| Earnings per Share | $2.08 |
| Beta | 0.68 |
| Outstanding Shares | 486,700,000 |
Return
| Return on Equity | 2.96% |
|---|---|
| Return on Assets | 2.06% |
| Return on Invested Capital | 1.54% |
Valuation & Multiples
| P/E Ratio | 49.32 |
|---|---|
| PEG | -49.32 |
| Price to Sales | 2.41 |
| Price to Book Ratio | 1.2 |
| Enterprise Value to Revenue | 3.26 |
| Enterprise Value to EBIT | 81.83 |
| Enterprise Value to Net Income | 55 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 0.25 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$0.60
Average shareholder expectationRevenue Estimate
$2.20 B
Average shareholder expectationNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$0.72
Average shareholder expectationRevenue Estimate
$2.24 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Alcon, Inc.
20,000 employees
CEO: David J. Endicott Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the followi...